

PANCREATIC CANCER

RESECTABLE AND BORDERLINE RESECTABLE

- A. Treatment Naïve
 - I. CA19-9 Producer (CA 19-9 > 35 U/mL, when total bilirubin 2 mg/dL)
 - a. PANC Trial - Phase II trial of adaptive neoadjuvant therapy
 - b. PANCREAS Trial – Tumor Subtype-directed Neoadjuvant Chemotherapy
 - II. CA19-9 Non-producer
 - a. SOFT Trial - Phase II RCT of IMRT vs SBRT prior to surgery
- B. Prior Neoadjuvant Chemotherapy
 - I. SOFT Trial - Phase II, RCT of IMRT vs SBRT prior to surgery
- C. Post Surgical Resection
 - I. PROTECT-PANC - Phase II, adjuvant therapy for patients at risk of cancer recurrence **(anticipated opening February 2024)**

LOCALLY ADVANCED

- A. Type A – potentially operable
 - I. SOFT Trial - Phase II, RCT of IMRT vs SBRT prior to surgery
- B. Prior Chemotherapy - Inoperable disease (locally advanced, oligometastatic for which all sites of metastases can be treated curatively, or medically inoperable)
 - I. CPI-613 - Phase I, CPI-613 (Devimistat) in combination with chemoradiation
- C. Post Surgical Resection
 - I. PROTECT-PANC - Phase II, adjuvant therapy for patients at risk of cancer recurrence **(anticipated opening February 2024)**

METASTATIC

- A. Phase 1 and 2
 - I. ASTELLAS-2138-CL-0101: Phase I/Ib, ASP2138 in Adults with Stomach Cancer or Pancreatic Cancer *(check for slot availability)*
 - II. MABSPACE-TST001-10010: Phase I, TST001 in Patients with Locally Advanced or Metastatic Solid Tumors *(check for slot availability)*
 - III. HOFFMANN-WO39608-MORPHEUS: Phase Ib/II, evaluating multiple immunotherapy-based treatment combinations *(check for slot availability)*
 - IV. HELIX-LDOS006: Phase I/II, Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin *(check for slot availability)*
 - VII. HOFFMAN-B041932-TAPISTRY: Phase II, Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational *(check for slot availability)*
 - VIII. PANBELLA-CL-SBP-101-04: Phase II/II, Nab-Paclitaxel and Gemcitabine with or without SBP-101

PANCREATIC NEUROENDOCRINE

- I. ALLIANCE-A022001-PNETS- Lutetium LU 177 Dotatate PRRT vs Capecitabine and Temozolomide in PNET

NEW CLINICAL TRIAL!

The PROTECT-PANC study is a prospective, open-label, therapeutic interventional trial designed to determine the efficacy and safety of personalized matched therapy given adjuvantly in pancreatic cancer patients who have completed all intended multimodal therapy, including resection of the pancreatic cancer tumor. This trial is anticipated to open at MCW in February 2024. For more information, contact Lori at 414-805-4627.

**ANTICIPATED
OPENING 2024**



clinicaltrials.mcw.edu



RESECTABLE & BORDERLINE RESECTABLE

Clinical Trial Name: Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients with Localized Pancreatic Cancer (PANC Trial)

Study Design: This is a single arm, Phase II clinical trial utilizing neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic adenocarcinoma which utilizes a total neoadjuvant therapy approach with adaptive modification of the chemotherapy regimen based on radiographic response (CT scan), biochemical response (CA19-9 decline), and performance status (as measured by a short physical performance battery).

NCT#: [NCT03322995](#)

Study PI: Dr. Kathleen Christians

Clinical Research Coordinator:
Megan Graham

Phone: 414-805-8921

Key Inclusion

- ECOG performance status of < 2
- Histologically confirmed adenocarcinoma of the pancreas
- Clinical stage resectable or borderline resectable pancreatic adenocarcinoma
- Must be CA19-9 producer (pretreatment CA19-9 > 35 U/mL when total bilirubin ≤ 2 mg/dL)

Key Exclusion:

- Received chemotherapy and/or radiation within 3 years prior to study enrollment
- History of prior malignancy except for adequately treated in situ cancer of the cervix or basal cell or squamous cell skin cancer or localized prostate cancer with a normal PSA within the last 3 years

Clinical Trial Name: PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Samples Study (PANCREAS)

Study Design: This is an open-label, single arm, phase II study in patients with resectable and borderline resectable pancreatic cancer. The study intervention involves molecular profiling Purity Independent Subtyping of Tumors (PurIST) subtyping of pretreatment Endoscopic Ultrasound Fine Needle Aspiration (EUS/FNA) samples to determine pancreatic cancer subtype. Neoadjuvant therapy is directed based on the molecular subtype (classical vs. basal). Patients with classical subtype will receive a standard chemotherapy (mFOLFIRINOX) and patients with basal subtype will receive an alternative standard therapy (gemcitabine/nab-paclitaxel).

NCT#: [NCT04683315](#)

Study PI: Dr. Kathleen Christians

Key Inclusion

Eligibility for screening consent:

- Suspicion of PDAC and plan for endoscopic biopsy or enough archival tissue to be requested from previous screening endoscopic biopsy. Agrees to additional EUS biopsy at the first restaging and tissue collection from surgical specimen
- CA19-9 level >35 mg/dL regardless of total bilirubin level

Eligibility for Treatment consent:

NEW PATIENT COORDINATOR: (414) 805-6849

Research Coordinator: Megan Graham Phone: 414-805-8921	<ul style="list-style-type: none"> • ECOG performance status < 2 • Histologically confirmed adenocarcinoma. Biopsy must have been completed prior to start of treatment • Clinical stage consistent with resectable or borderline resectable adenocarcinoma of the pancreas, based on CT or MRI findings • Adequate organ and bone marrow function, as defined by: total leukocytes >3 x10³/μL; ANC >1.5x 10³/μL; HgB >9 g/dL; platelets >100 x 10³/μL; creatinine clearance >60 mL/min or creatinine <1.5 mg/dL; bilirubin ≤2 mg/dL; AST/SGOT & ALT/SGPT <3 x ULN • CA19-9 producer, as defined by a pretreatment CA 19-9 > 35 U/mL, when total bilirubin ≤2 mg/dL. <p>Key Exclusion:</p> <ul style="list-style-type: none"> • Received chemotherapy and/or radiation within three years prior to study enrollment • Previous history of another malignancy w/in 3 years of study (other than cured basal or squamous cell carcinoma and other in situ carcinomas that were completely treated or localized prostate cancer with normal prostate specific antigen)
--	---

Clinical Trial Name: Stereotactic Body Radiation Therapy or Conventionally Fractionated Concurrent Chemotherapy and Radiation Therapy Preoperatively for Resectable or Borderline Resectable Pancreatic Adenocarcinoma (SOFT Trial)	
Study Design: This study is a prospective, open-label, randomized, parallel, two-arm, phase II clinical trial. Patients meeting the eligibility criteria will be randomized after a minimum of two months of induction chemotherapy. These patients will be required to have no biopsy-proven distant disease on repeat staging studies before randomization. Patients who have radiologically equivocal evidence of distant metastatic disease (small lung nodules, or liver lesions that cannot be definitively characterized, etc.) are also eligible for enrollment. Patients with biopsy-proven metastatic disease are not eligible.	
NCT#: NCT03704662	<p>Key Inclusion</p> <ul style="list-style-type: none"> • Confirmed, resectable/borderline resectable, locally advanced Type A pancreatic adenocarcinoma • Patients with and without regional adenopathy are eligible • No evidence of distant metastatic disease • ≥ 1 cycle of systemic chemotherapy without evidence of distant progression <p>Key Exclusion:</p> <ul style="list-style-type: none"> • Distant metastatic disease • Prior invasive malignancy within the last 3 years • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields • Major surgery within 28 days prior to study entry
Study PI: Dr. William Hall	
Research Coordinator: Kathryn Hallada Phone: 414-805-0124	

LOCALLY ADVANCED

Clinical Trial Name: Stereotactic Body Radiation Therapy or Conventionally Fractionated Concurrent Chemotherapy and Radiation Therapy Preoperatively for Resectable or Borderline Resectable Pancreatic Adenocarcinoma (SOFT Trial)

Study Design: This study is a prospective, open-label, randomized, parallel, two-arm, phase II clinical trial. Patients meeting the eligibility criteria will be randomized after a minimum of two months of induction chemotherapy. These patients will be required to have no biopsy-proven distant disease on repeat staging studies before randomization. Patients who have radiologically equivocal evidence of distant metastatic disease (small lung nodules, or liver lesions that cannot be definitively characterized, etc.) are also eligible for enrollment. Patients with biopsy-proven metastatic disease are not eligible.

NCT#: [NCT03704662](#)

Study PI: Dr. William Hall

Research Coordinator:
Kathryn Hallada

Phone: 414-805-0124

Key Inclusion

- Confirmed, resectable/borderline resectable, locally advanced Type A pancreatic adenocarcinoma
- Patients with and without regional adenopathy are eligible
- No evidence of distant metastatic disease
- ≥ 1 cycle of systemic chemotherapy without evidence of distant progression

Key Exclusion:

- Distant metastatic disease
- Prior invasive malignancy within the last 3 years
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
- Major surgery within 28 days prior to study entry

Clinical Trial Name: A Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination with Chemoradiation in Patients with Pancreatic Adenocarcinoma (CPI-613 with Gem-RT in PDAC)

Study Design: This study is a single site, open-label, phase I trial to investigate whether patients with pancreatic cancer (medically inoperable, locally advanced, or oligometastatic) that, by the consensus of the institutional pancreatic tumor board or multidisciplinary review, would benefit from chemoradiation for local control of the primary tumor. Therefore, this study aims to determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), and safety of CPI-613® in combination with chemoradiation.

NCT#: [NCT05325281](#)

Study PI: Dr. Mandana Kamgar

Research Coordinator:
Dawn Carini

Phone: 414-805- 0789

Key Inclusion

- Eligible patients should have an inoperable disease (locally advanced, oligometastatic for which all sites of metastases can be treated curatively, or medically inoperable) and, based on institutional pancreatic tumor board or multidisciplinary review, should otherwise benefit from chemoradiation for definitive local control of the primary tumor. Oligometastatic is defined as less than three total metastases planned to be treated with definitive therapy.
- ECOG 0-2
- Pathologically confirmed (histologic or cytologic) adenocarcinoma of the pancreas

Key Exclusion:

NEW PATIENT COORDINATOR: (414) 805-6849

- | | |
|--|--|
| | <ul style="list-style-type: none">• Prior invasive malignancy (except nonmelanomatous skin cancer, noninvasive breast cancer [ductal carcinoma in situ, or DCIS], or prostate cancer under active surveillance). Other malignancies are allowed if the patient has been disease free for a minimum of two years.• Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.• Concurrent therapy with approved or investigational anticancer therapeutics other than what is stipulated by the protocol. |
|--|--|

METASTATIC

PHASE I/II STUDIES

Clinical Trial Name: A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma (ASTELLAS).

Study Design: A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression.

NCT #:

[NCT05365581](#)

Study PI: Dr. Aditya Shreenivas

Research Coordinator:
Olivia Gorman

Phone:
414-805-6345

Key Inclusion:

- Tumor sample is positive for claudin (CLDN)18.2 expression by central immunohistochemistry (IHC) testing.
- Radiographically-confirmed, locally advanced, unresectable or metastatic disease within 28 days prior to the first dose of study intervention
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 28 days prior to the first dose of study intervention. For participant with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy.
- QT interval by Fredericia (QTcF) =< 470 msec.
- Participant has ECOG performance status of 0 or 1.
- Disease Specific Criteria: Pancreatic Cancer
 - Participant has histologically or cytologically confirmed pancreatic adenocarcinoma.
 - Participant with pancreatic adenocarcinoma who has progressed, is intolerant, has refused, or for whom there is no standard approved therapies that impart significant clinical (no limit to the number of prior treatment regimens).

Key Exclusion:

- Prior severe allergic reaction or intolerance to known ingredients of ASP2138 or other antibodies, including humanized or chimeric antibodies.
- Received systemic immunosuppressive therapy, including systemic corticosteroids 14 days prior to first dose of study intervention.
- Complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting.
- Gastric bleeding and/or untreated gastric ulcers that exclude the participant from participation.
- Symptomatic CNS metastases or participant has evidence of unstable CNS metastases even if asymptomatic.
- Known HIV infection.
- Participant is known to have active hepatitis B (positive hepatitis B surface antigen [HBsAg]) or hepatitis C infection. Testing is required for known history of these infections or as mandated by local requirements.
- Negative for HBsAg, but hepatitis B core antibody (HBc Ab) positive, a hepatitis B virus (HBV) deoxyribonucleic acid (DNA) test will be performed and if positive the participant will be excluded.
- Positive hepatitis C virus (HCV) serology, but negative HCV ribonucleic acid (RNA) test results are eligible.
- Treated for HCV with undetectable viral load results are eligible.
- Within 6 months prior to first dose of study intervention any of the following: unstable angina, myocardial infarction, ventricular arrhythmia requiring intervention or hospitalization for heart failure.
- Active infection requiring systemic therapy that has not completely resolved within 7 days prior to the start of study intervention.

NEW PATIENT COORDINATOR: (414) 805-6849

	<ul style="list-style-type: none"> • Active autoimmune disease that has required systemic immunosuppressive treatment within the past 1 month prior to the start of study intervention. • Major surgical procedure 28 days before start of study intervention and has not fully recovered. • Received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ or metastatic pancreatic adenocarcinoma 14 days prior to start of study intervention and has NOT recovered from any related toxicity. • Received an CLDN18.2-targeted investigational agent (e.g., zolbetuximab or chimeric antigen receptor CLDN18.2-specific T cells) prior to first dose of study intervention administration is not eligible for dose escalation cohorts. However, a participant who has received an CLDN18.2-targeted investigational agent greater than 28 days or 5 half-lives (whichever is longer) prior to first dose study intervention administration is eligible for dose expansion cohorts only, except for participants who have experienced Grade ≥ 3 gastrointestinal (GI) toxicity after receiving an CLDN18.2-targeted investigational agent. • History or complication of interstitial lung disease.
--	---

Clinical Trial Name: A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 in Patients with Locally Advanced or Metastatic Solid Tumors (MABSPACE-TST001-1001)

Study Design: This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic cancers.

NCT #: NCT04396821	<p>Key Inclusion:</p> <ul style="list-style-type: none"> • Histologically or cytologically confirmed, locally advanced or metastatic solid tumors. • Part A only: <ul style="list-style-type: none"> ▪ Patients must be a) progressed after standard therapies, b) intolerant of standard therapies, or c) with a tumor type without standard therapy. • Part B only: <ul style="list-style-type: none"> ▪ Cohort A: Patients with previously untreated, unresectable, locally advanced or metastatic GC/GEJ adenocarcinoma; prior adjuvant or neoadjuvant therapy are allowed only if disease progressed or recurred at least 6 months after completion of these treatments. Patients may have received one infusion of mFOLFOX6 plus nivolumab during the screening period. ▪ Cohort B: Patients with GC/GEJ adenocarcinoma who have radiologically progressed following one or two prior systemic therapies; adjuvant or neoadjuvant therapy could be regarded as one line of therapy only if disease progressed or recurred during these treatments or within 6 months or less after completion of these treatments. ▪ Cohort C: Patients with previously untreated, unresectable, locally advanced or metastatic histologically confirmed pancreatic adenocarcinoma; prior adjuvant or neoadjuvant therapy are allowed only if disease progressed or recurred at least 6 months after completion of these treatments. Patients may have received up to 2 infusions of Gemcitabine + albumin-bound paclitaxel (with one week between each infusion) during the screening period. • ECOG= 0-1. <p>Key Exclusion:</p> <ul style="list-style-type: none"> • Symptomatic central nervous system metastases. • Prior treatment with any CLDN18.2 target agents. • Allergy or sensitivity to TST001 or known allergies to comparable drugs. • Severe cardiovascular disease, including CVA, TIA, myocardial infarction, or unstable angina, NYHA class III or IV heart failure or uncontrolled arrhythmia within 6 months of study entry, severe QTc prolongation, concomitant risks for QTc prolongation.
Study PI: Dr. Ben George	
<p>Research Coordinator: Phone: Gabrielle Threatt</p> <p>Phone: 414-805-4767</p>	

NEW PATIENT COORDINATOR: (414) 805-6849

	<ul style="list-style-type: none"> • Concurrent malignancy within 5 years prior to entry except adequately treated certain types of cancer. • Active and clinically significant infections, known uncontrolled infections with hepatitis B, hepatitis C, known human immunodeficiency virus with acquired immunodeficiency syndrome related illness.
--	--

Clinical Trial Name: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants with Metastatic Pancreatic Ductal Adenocarcinoma (HOFFMANN-WO39608-MORPHEUS)

Study Design: A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

NCT #: NCT03193190	<p>Key Inclusion:</p> <ul style="list-style-type: none"> • ECOG= 0 or 1 • Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma • For patients in Cohort 1: no prior systemic treatment for PDAC • For patients in Cohort 2: disease progression during administration of either 5-FU- or gemcitabine-based first-line chemotherapy • Life expectancy greater than or equal to 3 months • Availability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central testing • Measurable disease (at least one target lesion) according to RECIST v1.1 • Adequate hematologic and end-organ function test results • Tumor accessible for biopsy <p>Key Exclusion:</p> <ul style="list-style-type: none"> • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage procedure (i.e., more than one time per month) • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases • History of leptomeningeal disease • Active or history of autoimmune disease or immune deficiency • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan • Active hepatitis B or C virus infection or active tuberculosis • Severe infection within 4 weeks prior to initiation of study treatment • Prior allogeneic stem cell or solid organ transplantation • History of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
Study PI: Dr. Ben George	
Research Coordinator: Aliece Novitski Phone: 414-805-3158	

Clinical Trial Name: A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients with Previously Treated Advanced Pancreatic Cancer (HELIX-LDOS006).

Study Design: This is an open-label, single arm study that includes an initial three cohort dose escalation phase with 3, 6 and 9 µg/kg of L-DOS47 in combination with doxorubicin.

NEW PATIENT COORDINATOR: (414) 805-6849

NCT #: NCT04203641	<p>Key Inclusion:</p> <ul style="list-style-type: none"> • ≥1 metastatic tumors measurable on CT scan per RECIST version 1.1 and screening FDG-PET scan with maximum standardized uptake value (SUV max) ≥ 5.5 for at least one lesion consistent with pancreatic cancer. • Karnofsky performance status ≥ 70%. • Acceptable liver function: Bilirubin ≤ 1.5 times upper limit of normal; Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and Alkaline phosphatase (ALP) ≤ 2.5 times upper limit of normal (ULN; if liver metastases are present, then ≤ 5 x ULN is allowed); Acceptable renal function as defined by creatinine ≤1.5x institutional upper limits of normal, or calculated creatinine clearance ≥ 60 mL/min/1.73 m² for patients with creatinine levels above institutional normal; Acceptable hematologic status: Granulocyte ≥ 1500 cells/mm³; Platelet count ≥ 100,000 (plt/mm³); Hemoglobin ≥ 9g/dL • Urinalysis: No clinically significant abnormalities. • Acceptable coagulation status: Prothrombin time within 1.5x of normal limits; Partial thromboplastin time (PTT) within 1.5x of normal limits. • Normal ejection fraction on ECHO or MUGA. <p>Key Exclusion:</p> <ul style="list-style-type: none"> • New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG. • Abnormal ejection fraction on ECHO or MUGA. • Active, uncontrolled bacterial, viral, or fungal infections requiring systematic therapy. • Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within 3 weeks prior to study entry. • Serious nonmalignant disease (eg hydro nephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor. • Patients with marked screening prolongation of QT/QTc interval (e.g. repeated demonstration of a QTc interval > 480 milliseconds (CTCAE grade 1) using Fredericia's QT correction formula.
Study PI: Dr. Ben George	
Research Coordinator: Catherine Feffer Phone: 414-805-8838	

Clinical Trial Name: Tumor-Agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	
Study Design: A study to evaluate the efficacy and safety of multiple therapies that are selected using somatic alterations and potential predictive biomarkers identified via NGS assays in patients with solid tumors.	
NCT #: NCT04589845	<p>Key Inclusion:</p> <ul style="list-style-type: none"> • Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy. • Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), Response Assessment in Neuro-Oncology (RANO) criteria, or International Neuroblastoma Response Criteria (INRC). • Performance status as follows: Participants aged ≥ 18 years: ECOG=0-2; Participants aged 16 to < 18 years: Karnofsky score ≥ 50%; Participants aged < 16 years: Lansky score ≥ 50% • For participants aged ≥ 18 and <18 years: adequate hematologic and end-organ function • Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment • Adequate recovery from most recent systemic or local treatment for cancer
Study PI: Dr. Ben George	

<p>Research Coordinator: Catherine Feffer</p> <p>Phone: 414-805-8838</p>	<ul style="list-style-type: none"> • Life expectancy ≥ 8 weeks • Ability to comply with the study protocol, in the investigator's judgment • For female participants of childbearing potential: Negative serum pregnancy test ≤ 14 days prior to initiating study treatment; agreement to remain abstinent or use single or combined contraception methods that result in a failure rate of $< 1\%$ per year for the period defined in the cohort-specific inclusion criteria; and agreement to refrain from donating eggs during the same period • For male participants: Willingness to remain abstinent or use acceptable methods of contraception as defined in the cohort-specific inclusion criteria • In addition to the general inclusion criteria above, participants must meet all the cohort-specific inclusion criteria for the respective cohort <p>Key Exclusion:</p> <ul style="list-style-type: none"> • Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study treatment. • Whole brain radiotherapy within 14 days prior to start of study treatment. • Stereotactic radiosurgery within 7 days prior to start of study treatment. • History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study. • Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment. • Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina. • History of another active cancer within 5 years prior to screening that may interfere with the determination of safety or efficacy of study treatment with respect to the qualifying solid tumor malignancy.
--	---

<p>Clinical Trial Name: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (PANBELLA-CL-SBP-101-04)</p>	
<p>Study Design: The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.</p>	
<p>NCT #: NCT05254171</p>	<p>Key Inclusion:</p> <ul style="list-style-type: none"> • Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma. Subjects with pancreatic acinar cell carcinoma may also be included. • Previously untreated for metastatic pancreatic ductal adenocarcinoma; metastatic disease must have been diagnosed within the past 3 months; and subject is expected to receive standard treatment with gemcitabine and nab-paclitaxel. Subjects who have had planned or prior surgery, such as a Whipple procedure, with or without neo-adjuvant/adjuvant chemotherapy may be included. • Life expectancy ≥ 3 months. • Measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI) scan by RECIST v1.1 criteria. • ECOG Performance Status= 0-1. • Adequate bone marrow, hepatic and renal function as outlined in protocol. • Corrected QT interval (QTc); QTc interval ≤ 470 msec at Baseline. <p>Key Exclusion:</p> <ul style="list-style-type: none"> • BRCA (BReast CAncer gene antigen) positive.
<p>Study PI: Dr. Mandana Kamgar</p>	
<p>Research Coordinator: Barb Dion</p>	

NEW PATIENT COORDINATOR: (414) 805-6849

Phone: 414-805-4639	<ul style="list-style-type: none"> • Subjects taking metformin. Diabetic subjects on treatment with metformin, or any other derivative thereof, must discontinue it while on study (other diabetic medications are allowed). • History of retinopathy or macular degeneration. • Presence of islet-cell or pancreatic neuroendocrine tumor or mixed adenocarcinoma-neuroendocrine carcinoma. • CNS malignancy or metastasis. Screening of asymptomatic subjects without history of CNS metastases is not required. • Serum albumin < 30 g/L (3.0 g/dL). • Occurrence of deep vein thrombosis (DVT) or portal vein occlusion, pulmonary embolism (PE), or other thromboembolic event during screening. • Presence of interstitial lung disease, pulmonary fibrosis, or pulmonary hypersensitivity reaction. • Myocardial infarction within the last 12 months, severe/unstable angina, symptomatic congestive heart failure New York Heart Association (NYHA) class III or IV. • Any history of hydroxychloroquine use (Plaquenil® and other brand names).
-------------------------------	---

PANCREATIC NEUROENDOCRINE

Clinical Trial Name: ALLIANCE-A022001-PNETS Lutetium LU 177 Dotatate PRRT vs Capecitabine and Temozolomide in PNET

Study Design: This is a phase II randomized, prospective trial of Lutetium LU 177 Dotatate PRRT versus Capecitabine and Temozolomide in well-differentiated pancreatic neuroendocrine tumors.

NCT#:

[NCT05247905](#)

Study PI: Dr. Callisia Clarke

Research Coordinator:
Barb Dion

Phone: 414-805-4639

Key Inclusion

- Histologic or pathologic documentation of well-differentiated pancreatic neuroendocrine tumor (G1, G2, or well-differentiated G3) confirmed by local histology and/or pathology. Functional or nonfunctional tumors are allowed.
- Stage: locally unresectable or metastatic disease.
- Tumor Site: neuroendocrine tumor of pancreatic primary site.
- Radiologic evaluation: tumor must have shown somatostatin receptor (SSTR) positivity on 68Ga-DOTATATE PET or other SSTR-PET scan in the 12 months prior to registration; however, documentation of SSTR positivity in the 6 months prior to registration is preferred. SSTR positivity is defined as uptake greater than background liver in all measurable lesions.
- Patients are eligible if they meet one of the following criteria:
 - Previously untreated patients with grade 2 or 3 disease AND with symptoms of either disease bulk causing pain, anorexia, early satiety, large effusions/ascites, abdominal pain, abdominal fullness due to hepatomegaly, dyspnea) OR incompletely controlled symptoms of hormone excess despite somatostatin analogue (SSA) and supportive care (including but not limited to: diarrhea, hypercalcemia, hypoglycemia, hyperglycemia, flushing, Cushing's syndrome). Patient may have been started on SSA for up to 2 months for attempted symptom control without disease progression prior to registration.
 - Patients previously treated with SSA only and with disease progression by RECIST in prior 12 months.
 - Patients previously treated with SSA and one or more prior systemic therapy must have received prior anti-vascular endothelial growth factor (VEGF) pathway therapy inhibitor OR have contraindication to anti-VEGF therapy (including but not limited to: uncontrolled hypertension [systolic blood pressure [SBP] > 150 and/or diastolic blood pressure [DBP] > 90 despite medical management], stage IIB or greater heart disease, angina pectoris, prior arterial [ATE] and venous thromboembolic [VTE] events in the past 6 months, gastrointestinal [GI] bleed in the last 6 months) and disease progression by RECIST in prior 12 months.
 - Patients previously treated with more than 2 lines of therapy, not including anti VEGF therapy, but with NET related symptoms as outlined in first bullet (pain, anorexia, early satiety, large effusions/ascites, abdominal pain, abdominal fullness due to hepatomegaly, anorexia, early satiety, dyspnea) OR incompletely controlled symptoms of hormone excess despite somatostatin analogue (SSA) and supportive care (including but not limited to: diarrhea, hypercalcemia, hypoglycemia, hyperglycemia, flushing, Cushing's syndrome).
 - Any patient with disease progression by RECIST criteria in < 4 months.
- Patients must have measurable disease per RECIST v1.1 by computer tomography (CT) scan or magnetic imaging (MRI). Any lesions which have undergone percutaneous therapies or radiotherapy after starting protocol therapy should not be considered measurable unless the lesion has clearly progressed since the procedure.
- Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 1 cm with CT or MRI (or shortest diameter ≥ 1.5 cm for lymph nodes). Non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, bone metastases, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung.

NEW PATIENT COORDINATOR: (414) 805-6849

- Prior treatment with tyrosine kinase inhibitors (TKIs) such as mammalian target of rapamycin (mTOR) inhibitors (e.g. everolimus, temsirolimus, etc.) or VEGF pathway inhibitors (e.g. sunitinib, pazopanib, cabozantinib, bevacizumab, etc.) are allowed.
- Prior treatment with hepatic intra-arterial embolic therapies is allowed if there is recovery from all toxicities, measurable lesions do not include embolized liver unless there has been clear subsequent progression, all measurable lesions are somatostatin receptor avid, and treatment completed at least 2 months prior to registration.
- Prior treatment with cryoablation or thermal/radiofrequency ablation of metastases is allowed if there is recovery from all toxicities, measurable lesions do not include treated metastases, and treatment completed at least 2 months prior to registration.
- ECOG = 0-2.
- Absolute neutrophil count (ANC) $\geq 1,500/\text{mm}^3$, Platelet count $\geq 100,000/\text{mm}^3$, Hemoglobin ≥ 9.0 g/dL, Creatinine ≤ 1.5 x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance ≥ 30 mL/min (calculated by the Cockcroft-Gault equation), Total bilirubin ≤ 1.5 x ULN (in patients with liver metastases or known Gilbert's syndrome, total bilirubin must be ≤ 3.0 x ULN), Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3.0 x ULN, Albumin ≥ 3.0 g/dL.
- Concurrent somatostatin analog use while on protocol therapy is allowed provided that the patient:
 - Has a functional tumor (evidence of peptide hormones and/or bioactive substances associated with a clinical hormone syndrome such as carcinoid syndrome or Cushing's syndrome).
 - Has been on a stable dose of somatostatin analog therapy for at least three months.
 - Has previously demonstrated radiographic disease progression while on somatostatin analog therapy. For subjects receiving lutetium Lu 177 dotatate, there should be a minimum of 14 days between long-acting somatostatin analogue and lutetium Lu 177 dotatate dosing. Short-acting somatostatin analogs should not be administered within 24 hours of lutetium Lu 177 dotatate dosing. Following lutetium Lu 177 dotatate dosing, long-acting somatostatin analogs may be administered between 4 and 24 hours after each dose.

Key Exclusion:

- Patients with poorly differentiated neuroendocrine carcinoma (large cell histology or small cell histology) are not eligible.
- No prior temozolomide, dacarbazine, capecitabine, 5-FU, or any PRRT for treatment of the pNET.
- No uncontrolled congestive heart failure (New York Heart Association [NYHA] II, III, IV).
- No "currently active" second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ. Patients are not considered to have a "currently active" malignancy if they have completed therapy or are on adjuvant hormonal therapy and are free of disease for ≥ 3 years.
- No known medical condition causing an inability to swallow and no known impairment of gastrointestinal function that may significantly alter the absorption of an oral agent.